文献速递慢性肾脏病肾小球疾病

基于公共转录组数据的慢性肾脏病实体功能图谱

A Functional Landscape of CKD Entities From Public Transcriptomic Data.
PubMed 文献 · Kidney Int Rep · 2019-11-13

该研究整合5项公开人类肾小球微阵列基因表达数据,覆盖全球多数慢性肾脏病(CKD)的9种肾脏疾病实体,与肾癌肾切除术非肿瘤对照组织比较。研究构建转录组扩散图谱展示各疾病实体的相似与差异,推断信号通路和转录因子活性并匹配药物候选,免疫染色验证FOXM1在急进性肾小球肾炎(RPGN)壁层上皮细胞特异性高表达,并发现尼洛替尼等候选药物。

要点

  • 整合5项公开研究构建9种CKD实体的肾小球转录组图谱,揭示疾病间分子相似与差异。
  • FOXM1在RPGN壁层上皮细胞显著特异性表达,对照肾组织不表达,经免疫染色验证。
  • 基于表达特征匹配发现FDA批准药物尼洛替尼等候选,但具体结果需谨慎解读。

核心结论

  • 整合公共转录组数据可勾勒不同肾脏疾病实体的分子特征,为识别生物标志物和潜在治疗靶点提供基础。
  • 研究结果通过免费交互式网络应用(https://saezlab.shinyapps.io/ckd_landscape/)公开,便于后续使用。
  • 因数据局限和整合困难,任何具体结果应谨慎看待,本研究更倾向于是功能基因组学和现有数据整合价值的例证。

研究设计与样本

  • 整合5项公开可用研究的人类肾小球微阵列基因表达数据,覆盖9种占全球CKD多数的肾脏疾病实体。
  • 对照为肾癌肾切除术组织的非肿瘤部分。
  • 采用定制的严格流程缓解不同来源、平台和条件数据整合的挑战。

主要发现

  • 基于各肾脏疾病实体与肾切除组织间一致差异表达基因,获得转录组扩散图谱展示疾病实体的相似与差异。
  • 从基因表达数据推断信号通路和转录因子活性获得功能见解,并通过表达特征匹配识别潜在药物候选。
  • 免疫染色人肾活检验证代表性发现,如转录因子FOXM1在急进性肾小球肾炎(RPGN)壁层上皮细胞显著且特异性表达,而对照肾组织不表达。
  • 通过匹配药物表达特征与CKD实体特征发现候选药物,尤其是FDA批准的尼洛替尼。

临床怎么用

  • 结果以免费交互式网络应用形式提供,肾内科医生可访问探索不同CKD实体的转录组特征。
  • FOXM1在RPGN壁层上皮细胞的特异性表达提示其可能作为该疾病的潜在生物标志物或靶点。
  • 基于表达特征匹配的药物候选(如尼洛替尼)需进一步验证,不应直接用于临床决策。

局限性

  • 数据本身存在局限性,且不同来源、平台和条件的数据整合困难。
  • 任何具体结果应谨慎解读,研究定位为功能基因组学和数据整合价值的例证而非确证性结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: To develop effective therapies and identify novel early biomarkers for chronic kidney disease, an understanding of the molecular mechanisms orchestrating it is essential. We here set out to understand how differences in chronic kidney disease (CKD) origin are reflected in gene expression. To this end, we integrated publicly available human glomerular microarray gene expression data for 9 kidney disease entities that account for most of CKD worldwide. Our primary goal was to demonstrate the possibilities and potential on data analysis and integration to the nephrology community. METHODS: We integrated data from 5 publicly available studies and compared glomerular gene expression profiles of disease with that of controls from nontumor parts of kidney cancer nephrectomy tissues. A major challenge was the integration of the data from different sources, platforms, and conditions that we mitigated with a bespoke stringent procedure. RESULTS: We performed a global transcriptome-based delineation of different kidney disease entities, obtaining a transcriptomic diffusion map of their similarities and differences based on the genes that acquire a consistent differential expression between each kidney disease entity and nephrectomy tissue. We derived functional insights by inferring the activity of signaling pathways and transcription factors from the collected gene expression data and identified potential drug candidates based on expression signature matching. We validated representative findings by immunostaining in human kidney biopsies indicating, for example, that the transcription factor FOXM1 is significantly and specifically expressed in parietal epithelial cells in rapidly progressive glomerulonephritis (RPGN) whereas not expressed in control kidney tissue. Furthermore, we found drug candidates by matching the signature on expression of drugs to that of the CKD entities, in particular, the Food and Drug Administration-approved drug nilotinib. CONCLUSION: These results provide a foundation to comprehend the specific molecular mechanisms underlying different kidney disease entities that can pave the way to identify biomarkers and potential therapeutic targets. To facilitate further use, we provide our results as a free interactive Web application: https://saezlab.shinyapps.io/ckd_landscape/. However, because of the limitations of the data and the difficulties in its integration, any specific result should be considered with caution. Indeed, we consider this study rather an illustration of the value of functional genomics and integration of existing data.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Tajti F, Kuppe C, Antoranz A, et al. A Functional Landscape of CKD Entities From Public Transcriptomic Data. Kidney Int Rep. 2019. PMID: 32043035. doi:10.1016/j.ekir.2019.11.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。